Synlogic Q2 2021 net loss narrows to $14.5M; PKU and Enteric Hyperoxaluria trials on track for 2H readouts

SYNLOGIC, INC.

2022-Q2 EPS reported -$0.63 revenue$246,000

Cash, equivalents, and investments of $115.5M as of June 30, 2021; runway into second half of 2023.
Net loss of $14.5M ($0.28/shr) vs. $15.5M ($0.44/shr) in Q2 2020; revenue of $0.2M from Roche IBD collaboration.
SYNB1618 Phase 2 PKU trial ongoing; Phase 1 of next-generation SYNB1934 initiated in July 2021.
SYNB8802 Enteric Hyperoxaluria Part B enrolling; proof-of-concept data expected in 2H 2021.
Combination arm of SYNB1891 (atezolizumab) Phase 1 in solid tumors; mature data expected by year-end.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.